Ruling Sets Up Patent Battle Over Growth Treatment

Law360, New York (July 6, 2006, 12:00 AM EDT) -- Having recently won summary judgment on several of their motions, the makers of two growth hormone treatments for children are gearing up for a November trial against a rival company.

A federal judge granted some of Tercica Inc.’s and Genentech Inc.’s motions for summary judgment last week in a patent infringement lawsuit brought against rival Insmed Inc. over the treatments.

But Judge Claudia Wilken of the United States District Court for the Northern District of California also ruled that Insmed’s predecessor, Celtrix, should be excluded from...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.